Literature DB >> 7430117

Structural and functional reconstitution of hepatic cytochrome P-450 in vivo. Reversal of allylisopropylacetamide-mediated destruction of the hemoprotein by exogenous heme.

G C Farrell, M A Correia.   

Abstract

After the heme moiety of hepatic cytochrome P-450 in rats had been destroyed by allylisopropylacetamide (AIA), intravenously injected heme significantly increased the cytochrome P-450 content and mixed function oxidase activity of liver microsomes. (The term "heme" is used throughout this paper for iron protorphyrin IX, irrespective of its redox state). In the absence of AIA treatment, heme administration failed to elicit these effects. The heme-mediated increase of cytochrome P-450 was most pronounced in phenobarbital-pretreated rats (46%), but was detectable also in 3-methylcholanthrene-pretreated (6%) and in untreated animals (7%). Restoration of mixed function oxidase activity by heme appeared to depend on reconstitution of cytochrome P-450 and was greatest for oxidases whose activity is stimulated by phenobarbital. Under optimal experimental conditions, heme enhanced the residual activity of ethylmorphine N-demethylase 3-fold when 92% of the initial enzyme activity had been destroyed by AIA. Reconstitution of cytochrome P-450 was dependent on the relative amount of cytochrome P-450 destroyed by AIA and on the dose of heme administered. Formation of holocytochrome P-450 appeared to be independent of apoprotein synthesis as it was unaffected by cycloheximide. Thus, reconstitution of cytochrome P-450 following AIA-mediated destruction of its original prosthetic heme reflects direct incorporation of administered heme into residual apoprotein in the endoplasmic reticulum. These findings demonstrate that exogenous heme can partially restore the structure and function of hepatic cytochrome P-450 following its drug-mediated destruction.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7430117

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

Review 1.  Regulation by heme of synthesis and intracellular translocation of delta-aminolevulinate synthase in the liver.

Authors:  G Kikuchi; N Hayashi
Journal:  Mol Cell Biochem       Date:  1981-06-09       Impact factor: 3.396

2.  Differential haemin-mediated restoration of cytochrome P-450 N-demethylases after inactivation by allylisopropylacetamide.

Authors:  L M Bornheim; A N Kotake; M A Correia
Journal:  Biochem J       Date:  1985-04-01       Impact factor: 3.857

3.  Haem arginate improves hepatic oxidative metabolism in variegate porphyria.

Authors:  O Tokola; P Mustajoki; J J Himberg
Journal:  Br J Clin Pharmacol       Date:  1988-12       Impact factor: 4.335

4.  Incorporation of haemoglobin haem into the rat hepatic haemoproteins tryptophan pyrrolase and cytochrome P-450.

Authors:  J F Wyman; J L Gollan; W Settle; G C Farrell; M A Correia
Journal:  Biochem J       Date:  1986-09-15       Impact factor: 3.857

5.  Effects of repeated intravenous administration of haem arginate upon hepatic metabolism of foreign compounds in rats and dogs.

Authors:  O Tokola
Journal:  Br J Pharmacol       Date:  1987-04       Impact factor: 8.739

6.  Role of haem in the induction of cytochrome P-450 by phenobarbitone. Studies in chick embryos in ovo and in cultured chick embryo hepatocytes.

Authors:  U Giger; U A Meyer
Journal:  Biochem J       Date:  1981-08-15       Impact factor: 3.857

7.  Formation of cytochrome P-450 containing haem or cobalt-protoporphyrin in liver homogenates of rats treated with phenobarbital and allylisopropylacetamide.

Authors:  H L Bonkovsky; J F Sinclair; J F Healey; P R Sinclair; E L Smith
Journal:  Biochem J       Date:  1984-09-01       Impact factor: 3.857

8.  Repeated treatment with furazolidone induces multiple cytochrome p450-related activities in chicken liver, but not in rat liver.

Authors:  Nobuo Sasaki; Tomoyuki Matumoto; Yoshinori Ikenaka; Shouta M M Nakayama; Mayumi Ishizuka; Akio Kazusaka; Shoichi Fujita
Journal:  J Vet Med Sci       Date:  2013-06-18       Impact factor: 1.267

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.